Notice2023-01802
Advisory Committee on Immunization Practices
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 30, 2023
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. The meeting will be webcast live via the World Wide Web.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 19 (Monday, January 30, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 19 (Monday, January 30, 2023)]
[Notices]
[Pages 5883-5884]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-01802]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2023-0007]
Advisory Committee on Immunization Practices
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with regulatory provisions, the Centers for
Disease Control and Prevention (CDC) announces the following meeting of
the Advisory Committee on Immunization Practices (ACIP). This meeting
is open to the public. Time will be available for public comment. The
meeting will be webcast live via the World Wide Web.
DATES: The meeting will be held on February 22, 2023, 8 a.m. to 5:15
p.m., EST, February 23, 2023, 8 a.m. to 5 p.m., EST, and February 24,
2023, 8 a.m. to 1 p.m., EST (times subject to change, see the ACIP
website for updates: <a href="http://www.cdc.gov/vaccines/acip/index.html">http://www.cdc.gov/vaccines/acip/index.html</a>).
Written comments must be received between February 6-17, 2023.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0007, by any of the following methods below. CDC does not accept
comments by email.
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments.
<bullet> Mail: ACIP Meeting, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027.
Docket No. CDC-2023-0007.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the <a href="https://www.regulations.gov">https://www.regulations.gov</a> suitability policy will be posted
without change to <a href="https://www.regulations.gov">https://www.regulations.gov</a>, including any personal
information provided. For access to the docket to read background
documents or comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
[[Page 5884]]
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MSH24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8836;
Email: <a href="/cdn-cgi/l/email-protection#2160626871614245420f464e57"><span class="__cf_email__" data-cfemail="79383a3029391a1d1a571e160f">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines For Children program, along with
schedules regarding dosing interval, dosage, and contraindications to
administration of vaccines. Further, under provisions of the Affordable
Care Act, section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been approved by the Director,
CDC, and appear on CDC immunization schedules must be covered by
applicable health plans.
Matters To Be Considered: The agenda will include discussions on
mpox vaccines, influenza vaccines, pneumococcal vaccine, rotavirus
vaccines, varicella vaccines, meningococcal vaccines, Polio vaccine,
respiratory syncytial virus vaccine pediatric/maternal, respiratory
syncytial virus vaccine adult, dengue vaccines, Chikungunya vaccine,
and COVID-19 vaccines. Recommendation votes on mpox vaccine are
scheduled. A Vaccines For Children vote on rotavirus vaccines is
scheduled. Agenda items are subject to change as priorities dictate.
For more information on the meeting agenda visit <a href="https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html">https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html</a>.
Meeting Information: The meeting will be webcast live via the World
Wide Web; for more information on ACIP, please visit the ACIP website:
<a href="http://www.cdc.gov/vaccines/acip/index.html">http://www.cdc.gov/vaccines/acip/index.html</a>.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket. CDC does not accept comments by
email.
Written Public Comment: The docket will be opened to receive
written comments on February 6, 2023. Written comments must be received
by February 17, 2023.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines For Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the February 22, 2023 ACIP meeting must
submit a request at <a href="http://www.cdc.gov/vaccines/acip/meetings/">http://www.cdc.gov/vaccines/acip/meetings/</a> no later
than 11:59 p.m., EST, February 17, 2023 according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by February 20, 2023. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to three minutes, and each
speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-01802 Filed 1-27-23; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 30, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.